Wnt/β‑catenin signaling: Causes and treatment targets of drug resistance in colorectal cancer (Review)

Mol Med Rep. 2021 Feb;23(2):105. doi: 10.3892/mmr.2020.11744. Epub 2020 Dec 10.

Abstract

Colorectal cancer (CRC) is the third most common malignant tumor in humans. Chemotherapy is used for the treatment of CRC. However, the effect of chemotherapy remains unsatisfactory due to drug resistance. Growing evidence has shown that the presence of highly metastatic tumor stem cells, regulation of non‑coding RNAs and the tumor microenvironment contributes to drug resistance mechanisms in CRC. Wnt/β‑catenin signaling mediates the chemoresistance of CRC in these three aspects. Therefore, the present study analyzed the abundant evidence of the contribution of Wnt/β‑catenin signaling to the development of drug resistance in CRC and discussed its possible role in improving the chemosensitivity of CRC, which may provide guidelines for its clinical treatment.

Keywords: colorectal cancer; Wnt/β‑catenin signaling; drug resistance; tumor stem cells; non-coding RNAs; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / metabolism
  • Colorectal Neoplasms* / pathology
  • Drug Delivery Systems*
  • Drug Resistance, Neoplasm* / drug effects
  • Drug Resistance, Neoplasm* / genetics
  • Humans
  • Neoplasm Metastasis
  • Neoplastic Stem Cells* / metabolism
  • Neoplastic Stem Cells* / pathology
  • Wnt Signaling Pathway* / drug effects
  • Wnt Signaling Pathway* / genetics